These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17583372)

  • 1. Sirolimus (rapamycin): from the soil of Easter Island to a bright future.
    Paghdal KV; Schwartz RA
    J Am Acad Dermatol; 2007 Dec; 57(6):1046-50. PubMed ID: 17583372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus: a therapeutic advance for dermatologic disease.
    Peters T; Traboulsi D; Tibbles LA; Mydlarski PR
    Skin Therapy Lett; 2014; 19(4):1-4. PubMed ID: 25188522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
    Stallone G; Schena A; Infante B; Di Paolo S; Loverre A; Maggio G; Ranieri E; Gesualdo L; Schena FP; Grandaliano G
    N Engl J Med; 2005 Mar; 352(13):1317-23. PubMed ID: 15800227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient.
    Yilmaz R; Akoglu H; Kirkpantur A; Kilickap S; Arici M; Altun B; Aki T; Erdem Y; Yasavul U; Turgan C
    Ren Fail; 2007; 29(1):103-5. PubMed ID: 17365918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sirolimus and regression of Kaposi's sarcoma in immunosuppressed transplant patient.
    Pranteda G; Feliziani G; Grimaldi M; Paleologo G; Pranteda G; Melotti F; Camplone G
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):1022-3. PubMed ID: 18194240
    [No Abstract]   [Full Text] [Related]  

  • 6. Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient.
    Ho CM; Huang SF; Hu RH; Ho MC; Wu YM; Lee PH
    Clin Transplant; 2010; 24(1):127-32. PubMed ID: 19919613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of Kaposi's sarcoma in the rapamycin era].
    Gemelli A; Paciolla A; Oliosi F; Basso A; Moscardin R; Tineo MC; Romano P; Alaibac M; Aversa S; Furian L; D'Angelo A; Bonfante L
    G Ital Nefrol; 2009; 26(1):90-3. PubMed ID: 19255968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of post-transplant Kaposi's sarcoma using sirolimus.
    Kolhe N; Mamode N; Van der Walt J; Pattison J
    Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
    Campistol JM; Schena FP
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kaposi's sarcoma after renal transplantation.
    Kanitakis J
    N Engl J Med; 2005 Aug; 353(8):846-7; author reply 846-7. PubMed ID: 16120869
    [No Abstract]   [Full Text] [Related]  

  • 11. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression.
    Stallone G; Infante B; Grandaliano G; Schena FP; Gesualdo L
    Transpl Int; 2008 Sep; 21(9):825-32. PubMed ID: 18498314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimizing the risk of posttransplant malignancy.
    Campistol JM
    Transplantation; 2009 Apr; 87(8 Suppl):S19-22. PubMed ID: 19384182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
    Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
    Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin for Kaposi's sarcoma and graft-versus-host disease in bone marrow transplant recipient.
    Marco de F; Infante B; Giovanni S; Gesualdo L
    Transplantation; 2010 Mar; 89(5):633-4. PubMed ID: 20216371
    [No Abstract]   [Full Text] [Related]  

  • 16. Sirolimus for Kaposi's sarcoma.
    Wasywich CA; Croxson MC; van Doornum GJ; Coverdale HA; Ruygrok PN
    J Heart Lung Transplant; 2006 Jun; 25(6):726-9. PubMed ID: 16730579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment.
    Guenova E; Metzler G; Hoetzenecker W; Berneburg M; Rocken M
    Arch Dermatol; 2008 May; 144(5):692-3. PubMed ID: 18490609
    [No Abstract]   [Full Text] [Related]  

  • 19. Sirolimus--challenging current perspectives.
    Buhaescu I; Izzedine H; Covic A
    Ther Drug Monit; 2006 Oct; 28(5):577-84. PubMed ID: 17038868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
    Leblanc KG; Hughes MP; Sheehan DJ
    Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.